DE60024242T2 - Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion - Google Patents

Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion Download PDF

Info

Publication number
DE60024242T2
DE60024242T2 DE60024242T DE60024242T DE60024242T2 DE 60024242 T2 DE60024242 T2 DE 60024242T2 DE 60024242 T DE60024242 T DE 60024242T DE 60024242 T DE60024242 T DE 60024242T DE 60024242 T2 DE60024242 T2 DE 60024242T2
Authority
DE
Germany
Prior art keywords
carbon atoms
branched
lxa
methyl
lipoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024242T
Other languages
German (de)
English (en)
Other versions
DE60024242D1 (de
Inventor
N. Charles SERHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of DE60024242D1 publication Critical patent/DE60024242D1/de
Application granted granted Critical
Publication of DE60024242T2 publication Critical patent/DE60024242T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60024242T 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion Expired - Lifetime DE60024242T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
US125205P 1999-03-18
PCT/US2000/006582 WO2000054767A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response

Publications (2)

Publication Number Publication Date
DE60024242D1 DE60024242D1 (de) 2005-12-29
DE60024242T2 true DE60024242T2 (de) 2006-12-14

Family

ID=22418647

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024242T Expired - Lifetime DE60024242T2 (de) 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion

Country Status (11)

Country Link
US (6) US6387953B1 (https=)
EP (1) EP1165066B1 (https=)
JP (1) JP4440481B2 (https=)
AT (1) ATE310512T1 (https=)
AU (1) AU775140B2 (https=)
CA (3) CA2615917C (https=)
DE (1) DE60024242T2 (https=)
DK (1) DK1165066T3 (https=)
ES (1) ES2249257T3 (https=)
HK (1) HK1043307B (https=)
WO (1) WO2000054767A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
CA2675416A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
PT1406698E (pt) * 2001-03-02 2009-01-12 Brigham & Womens Hospital Análogos de lipoxina como novos inibidores da angiogénese
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
JP4652685B2 (ja) * 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2005216298B2 (en) 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
WO2011050126A1 (en) * 2009-10-21 2011-04-28 University Of Medicine And Dentistry Of New Jersey Method for treating sepsis or septic shock
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
US20220040136A1 (en) 2018-10-09 2022-02-10 University Of Rochester Treatment of vulvovaginal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512023A (ja) * 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
CA2675416A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.

Also Published As

Publication number Publication date
US6703423B2 (en) 2004-03-09
US6387953B1 (en) 2002-05-14
US20080312323A1 (en) 2008-12-18
US20040192785A1 (en) 2004-09-30
CA2615917C (en) 2011-10-04
US20080081838A1 (en) 2008-04-03
US20020132847A1 (en) 2002-09-19
CA2615917A1 (en) 2000-09-21
JP2002539159A (ja) 2002-11-19
HK1043307B (en) 2006-02-03
AU3880600A (en) 2000-10-04
ES2249257T3 (es) 2006-04-01
EP1165066A1 (en) 2002-01-02
HK1043307A1 (en) 2002-09-13
CA2747376A1 (en) 2000-09-21
ATE310512T1 (de) 2005-12-15
WO2000054767A1 (en) 2000-09-21
DE60024242D1 (de) 2005-12-29
AU775140B2 (en) 2004-07-22
CA2367909C (en) 2008-02-12
EP1165066B1 (en) 2005-11-23
US6710084B2 (en) 2004-03-23
JP4440481B2 (ja) 2010-03-24
US7132451B2 (en) 2006-11-07
CA2367909A1 (en) 2000-09-21
US20020143069A1 (en) 2002-10-03
DK1165066T3 (da) 2006-03-06

Similar Documents

Publication Publication Date Title
DE60024242T2 (de) Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion
DE69711894T2 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
DE60022327T2 (de) Lipoxinverbindungen und ihre anwendung
DE69837295T2 (de) Bernsteinsäureester von Probucol zur Hemmung der Expression von VCAM-1
DE69929810T2 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
AU2008216965B2 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
DE69835441T2 (de) Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
DE69528291T2 (de) Nicht-beta oxidierbare fettsäureanaloge,deren verwendung als therapeutisch wirksame medikamente sowie deren herstellung
DE60218153T2 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69220050T2 (de) Verfahren zur inhibierung der fibrose
US20050239889A1 (en) In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
AU2007214312B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
AU2004222825B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
EP1616566A1 (en) Lipoxin compounds for treating TNF-alpha initiated inflammation
EP1911448B1 (en) Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
HK1078497A (en) Lipoxin compounds for treating tnf-alpha initiated inflammation
DE2759987C2 (de) Arzneimittel mit Wirkung als Prostaglandinsynthetaseninhibitor
DE1518392A1 (de) Verfahren zur Herstellung von (4-Phenoxy-3,5-dijod-phenyl)-alkanolen bzw. deren A?ylaten und Phosphaten
DE102004050952A1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition